NRAS and cancer: Furthermore, Radkay et al. demonstrated that the risk of cancer is highly dependent on the RAS mutation subtype, with KRAS (41.7%) being associated with the lowest risk, followed by NRAS (86.8%) and HRAS mutations (95.5%) [33].